www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Companies

Glaxo names Emma Walmsley as new CEO to succeed Andrew Witty

(China Daily) Updated: 2016-09-23 10:52

Glaxo names Emma Walmsley as new CEO to succeed Andrew Witty

Emma Walmsley

GlaxoSmithKline Plc promoted Emma Walmsley to be its new chief executive officer and succeed Andrew Witty when he retires, singling out the UK's largest drugmaker as the only major global pharmaceutical company led by a woman.

Walmsley currently leads Glaxo's consumer health business. She will join the board on Jan 1 and take the helm of the London-based company on March 31, Glaxo said in a statement on Tuesday.

The 47-year-old Oxford graduate, whose background is in marketing rather than science, will be tasked with piloting cutting-edge treatments for cancer and infectious diseases through clinical tests and onto pharmacy shelves to boost earnings and revive Glaxo's shares. Chairman Phil Hampton had said he was seeking outside as well as inside for a new leader.

"I think it's actually better to have somebody who's more familiar with Glaxo, from working on the inside, rather than an external candidate," said Stephen Bailey, a fund manager at Liontrust Investment Partners LLP in London with 800 million pounds ($1 billion) under management, including Glaxo shares. "I would assume in the long term the likelihood is that the consumer division is split away."

No Science

As was the case for Joe Jimenez when he took over at rival Novartis AG, Walmsley's background isn't rooted in pharmaceuticals.

She joined the British drugmaker in 2010 from French cosmetics giant L'Oreal SA where she spent 17 years, holding marketing and general management roles in China and the US.

While living in Shanghai with her husband David and four children, Walmsley attended a networking lunch with Witty, she wrote in an online blog posting for Sheryl Sandberg's Lean In website.

Bungee Jump

"An inspiring conversation ended up spiraling into a job offer alarmingly fast," Walmsley said. The opportunity to run a business with operations in 100 countries, 5 billion pounds in sales and thousands of employees seemed overwhelming. She was plagued with concerns that she was being disloyal to L'Oreal, and unfair to her family.

Accepting Witty's offer felt like a "bungee jump"-but one she took with her husband's support.

At Glaxo, Walmsley joined the over-the-counter products business, first as president and then as CEO in 2015, following a three-part transaction with Novartis AG. She holds a degree in classics and modern languages from Oxford University.

The stock has climbed about 40 percent during Witty's tenure at the helm. That's in line with Novartis's performance, though it lags behind local rival AstraZeneca Plc's 140 percent advance.

Under Walmsley's leadership, core operating margins at the consumer unit doubled to 14 percent in the quarter ended June from a year earlier, bringing Glaxo closer to its aim of 20 percent operating profit margin for the division by 2020.

Few Women

Picking Walmsley means Glaxo probably will retain its consumer business rather than split it off, analysts at Liberium Capital said in a note to clients. Witty has described a view of the industry in which companies must move away from single blockbuster medicines and instead build a broad stable of solid earners such as vaccines and consumer products. In a March interview, Witty said the consumer health business-known for its Sensodyne toothpaste and Tums antacids-could in a few years generate enough cash to cover half the dividend Glaxo pays to investors.

Walmsley will join a small pool of women leaders in the pharmaceutical world. Among them are Heather Bresch, who heads the much smaller Mylan NV. Her promotion also makes her the first female chief among the FTSE100's biggest companies.

Others include Imperial Brands Plc's Alison Cooper, Royal Mail Plc's Moya Greene, Severn Trent Plc's Olivia Garfield, Kingfisher Plc's Veronique Laury-Deroubaix, EasyJet Plc's Carolyn Julia McCall.

That may be one reason why even some investors who'd called for a very different person to replace Witty-someone from outside the company with science experience-rallied behind her.

"While Emma doesn't have a lot of drug development experience, I think the drug world is changing," said Dan Mahony, a fund manager at Polar Capital LLP in London, which owns shares of Glaxo. "It's not just about getting data to get drugs approved. It's also about getting data to get drugs reimbursed and paid for-and that's all about generating value and effectiveness and real-world data. That's what consumer products are about."

Witty has run Glaxo for almost a decade. Once hailed as one of the pharmaceutical industry's most visionary managers, the 52-year-old has faced criticism for Glaxo's lagging share performance and sluggish sales. A bribery scandal in China that led to a $489 million fine last year also tarnished his image, which he had built with initiatives to develop the world's first malaria vaccine and reform the way medicines are marketed to doctors.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 神马我我不卡伦影视 | 欧美日韩精品在线播放 | 美女黄页网| 99久久精品视香蕉蕉er热资源 | 华人色| 一级a级国产不卡毛片 | 亚洲精品中文字幕一区 | 成人国产三级在线播放 | 国产欧美视频在线观看 | 国产精品视频九九九 | 亚洲欧美综合视频 | 6080伦理久久亚洲精品 | 黄色美女网站视频 | 中文字幕亚洲不卡在线亚瑟 | 成人欧美一区在线视频在线观看 | 欧美成人激情在线 | 久久免费视屏 | 精品久久九九 | 美女扒开腿让男人桶个爽 | 99re66热这里只有精品免费观看 | a级成人高清毛片 | 国产成人a视频在线观看 | 亚洲精品久久一区二区无卡 | 国产精品久久久精品三级 | 黄色免费看片网站 | 亚洲欧美国产精品专区久久 | 成年女人免费毛片视频永久 | 成人精品一区二区久久 | 怡红院美国十次成人影院 | 91aaa免费免费国产在线观看 | 久久精品国产这里是免费 | 最新国产美女一区二区三区 | 欧美一区在线观看视频 | 91久久青青草原免费 | 美女做爰视频在线观看免费 | 99色视频在线观看 | 亚洲欧美日本视频 | 久久免费小视频 | 国产在线观看免费 | 在线中文字幕视频 | 午夜精品网 |